Concord Biotech IPO A Good Investment for Pharma Sector
08/08/2023 Financial & Legal Services
Price: 226006.00 ₹
Description
Concord Biotech is coming up with an IPO. The company is a leading manufacturer of fermentation-based APIs and has a strong track record of growth. The IPO is priced at a reasonable valuation, and it could be a good investment opportunity for investors looking for exposure to the pharma sector.
Concord Biotech Limited is a pharmaceutical company that develops, manufactures, and markets APIs (active pharmaceutical ingredients) for the global market. The company is coming up with an initial public offering (IPO) of 20,925,652 equity shares of ₹10 each. The IPO is priced at ₹705 to ₹741 per share, with a face value of ₹10. The issue opens for subscription on August 4, 2023, and closes on August 8, 2023.
Comments
Sonu Kumar
Individual
More Details